Published in Lancet on February 12, 2000
Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ (2005) 6.08
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol (2010) 3.27
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol (2015) 2.60
Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Ann Surg (2003) 1.91
Patterns and correlates of local therapy for women with ductal carcinoma-in-situ. J Clin Oncol (2005) 1.53
Breast cancer guidelines for Uganda (2nd Edition 2008). Afr Health Sci (2008) 1.23
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2001) 1.22
HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2012) 1.22
A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer (2010) 1.18
Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res (2005) 1.18
Comparison of 1- and 2-year screening intervals for women undergoing screening mammography. Br J Cancer (2005) 1.16
Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer (2001) 1.15
Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project. Br J Cancer (2007) 1.10
Benefits of irradiation for DCIS: a Pyrrhic victory. Lancet (2000) 1.08
Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast. Ann Surg Oncol (2007) 1.03
Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol (2007) 1.00
Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol (2007) 0.99
Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. Br J Cancer (2006) 0.99
Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. Br J Cancer (2002) 0.99
Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). CMAJ (2001) 0.97
Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res (2009) 0.97
The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ. Br J Cancer (2008) 0.95
The diagnosis and management of pre-invasive breast disease: problems associated with management of pre-invasive lesions. Breast Cancer Res (2003) 0.92
Oncoplastic surgery after mammary reduction and mastopexy for bilateral breast cancer lesions: report of a case. Surg Today (2008) 0.90
Comparison of accelerated partial breast irradiation via multicatheter interstitial brachytherapy versus whole breast radiation. Radiat Oncol (2012) 0.87
Ductal carcinoma in situ: what the pathologist needs to know and why. Int J Breast Cancer (2013) 0.86
Low CD10 mRNA expression identifies high-risk ductal carcinoma in situ (DCIS). PLoS One (2010) 0.85
Intraoperative Electron Radiotherapy (IOERT) as an Alternative to Standard Whole Breast Irradiation: Only for Low-Risk Subgroups? Breast Care (Basel) (2014) 0.85
A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ. Int J Breast Cancer (2013) 0.84
Web based pathology assessment in RTOG 98-04. J Clin Pathol (2014) 0.84
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma in Situ. Pract Radiat Oncol (2016) 0.83
Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ. Ann Surg Oncol (2016) 0.82
Biological Markers Predictive of Invasive Recurrence in DCIS. Clin Med Oncol (2008) 0.82
A review of current practices in breast conservation surgery in the UK. Ann R Coll Surg Engl (2007) 0.82
Racial disparities in risk of second breast tumors after ductal carcinoma in situ. Breast Cancer Res Treat (2014) 0.81
Local control of ductal carcinoma in situ based on tumor and patient characteristics: the surgeon's perspective. J Natl Cancer Inst Monogr (2010) 0.81
Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast. Br J Cancer (2004) 0.80
Esthetic result of rhomboid flap repair after breast-conserving surgery for lower quadrant breast cancer lesion with skin invasion: report of two cases. Surg Today (2011) 0.80
Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast. Br J Cancer (2003) 0.80
The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden. Breast Cancer Res (2016) 0.80
Ductal carcinoma in situ of the breast: a surgical perspective. Int J Surg Oncol (2012) 0.80
An adequate margin of excision in ductal carcinoma in situ. BMJ (2005) 0.80
Modern concepts of ductal carcinoma in situ (DCIS) and its diagnosis through percutaneous biopsy. Eur Radiol (2007) 0.78
Breast cancer (non-metastatic). BMJ Clin Evid (2011) 0.77
Breast cancer and funnel chest. Comparing helical tomotherapy and three-dimensional conformal radiotherapy with regard to the shape of pectus excavatum. Strahlenther Onkol (2012) 0.77
No excess mortality in patients aged 50 years and older who received treatment for ductal carcinoma in situ of the breast. Int J Surg Oncol (2012) 0.76
Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey. Geburtshilfe Frauenheilkd (2016) 0.75
Radiotherapy in the management of early breast cancer. J Med Radiat Sci (2013) 0.75
Adjuvant radiotherapy for DCIS. Lancet (2000) 0.75
Structural estimates of treatment effects on outcomes using retrospective data: an application to ductal carcinoma in situ. Med Care Res Rev (2011) 0.75
Adjuvant radiotherapy for DCIS. Lancet (2000) 0.75
Adjuvant radiotherapy for DCIS. Lancet (2000) 0.75
Clinical experience of patients with ductal carcinoma in situ of the breast treated with breast-conserving surgery plus radiotherapy: a preliminary report. Cancer Res Treat (2005) 0.75
Final results from a multicenter prospective study ( JROSG 05-5) on postoperative radiotherapy for patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or less. J Radiat Res (2015) 0.75
Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years. Ann Surg Oncol (2016) 0.75
Adjuvant radiotherapy for DCIS. Lancet (2000) 0.75
Role of the radiotherapy boost on local control in ductal carcinoma in situ. Int J Surg Oncol (2012) 0.75
Breast cancer (non-metastatic). BMJ Clin Evid (2007) 0.75
Evaluation of the therapeutic efficacy of sequential therapy involving percutaneous microwave ablation in combination with 131I-hypericin using the VX2 rabbit breast solid tumor model. PLoS One (2015) 0.75
Breast carcinoma in situ: An observational study of tumor subtype, treatment and outcomes. Oncotarget (2016) 0.75
Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer. J Cancer (2017) 0.75
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 6.24
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst (2000) 4.15
Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet (1991) 4.09
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Stress and relapse of breast cancer. BMJ (1989) 3.07
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr (2010) 2.91
The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer (1999) 2.89
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
Familial breast cancer. BMJ (1994) 2.54
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Who needs steroid receptor assays? Lancet (1989) 2.27
Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg (1989) 2.23
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol (2001) 2.21
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
Is there a future for neutron capture therapy? Int J Radiat Oncol Biol Phys (1996) 2.08
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res (1995) 1.96
Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr (1992) 1.89
Surgical treatment of phyllodes tumors of the breast. Cancer (1989) 1.89
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Risk factors in breast-conservation therapy. J Clin Oncol (1994) 1.82
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect (1998) 1.82
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiother Oncol (2000) 1.76
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol (1999) 1.74
A controlled trial of short-term versus standard axillary drainage after axillary clearance and iridium implant treatment of early breast cancer. Ann R Coll Surg Engl (1991) 1.72
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Application of the van nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macroscopic sectioning: practical considerations. Breast Cancer Res Treat (2000) 1.69
Prognostic factors of neck node metastasis. Clin Otolaryngol Allied Sci (1982) 1.67
Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2013) 1.65
An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis (1998) 1.63
Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol (1998) 1.61
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract]. Actas Urol Esp (2011) 1.59
EORTC Late Effects Working Group. Late Effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys (1995) 1.59
Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer (1995) 1.58
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol (1995) 1.58
The impact of treatment time and smoking on local control and complications in T1 glottic cancer. Int J Radiat Oncol Biol Phys (1998) 1.57
Postmastectomy radiotherapy: questions for the twenty-first century. J Clin Oncol (1998) 1.55
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
TNM classification of genitourinary tumours 1987--position of the EORTC Genitourinary Group. Br J Urol (1988) 1.55
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol (1987) 1.53
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol (2000) 1.53
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol (2000) 1.51
Male breast cancer. Int J Clin Pract (2000) 1.51
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. Eur Urol (2004) 1.47
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat (1995) 1.46
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol (2010) 1.45
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol (2001) 1.44
A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. Eur J Surg Oncol (2008) 1.44
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group. Radiother Oncol (2001) 1.43
[Diagnostics in clinically occult, radiologically suspect breast lesions more often surgery than needle diagnostics with image monitoring]. Ned Tijdschr Geneeskd (2001) 1.43
Surgical correction of gynaecomastia in bodybuilders. Br J Clin Pract (1995) 1.43
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
Follow-up of patients with aspirated breast cysts is necessary. Arch Surg (1989) 1.41
The benefits of participation in clinical trials. Eur J Surg Oncol (1996) 1.41
Profile of radiotherapy departments contributing to the Cooperative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Int J Radiat Oncol Biol Phys (1996) 1.40
Additional copies of 1q in sequential samples from a phyllodes tumor of the breast. Cancer Genet Cytogenet (1995) 1.40
Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer (2005) 1.40
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2004) 1.40
A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer (2005) 1.40
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol (1991) 1.39
14. Breast cancer prevention. Int J Clin Pract (2002) 1.38
[Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma]. Ned Tijdschr Geneeskd (1993) 1.38
[Radiotherapy of the neck as a risk factor for stroke]. Ned Tijdschr Geneeskd (2005) 1.38